Gachon University Gil Oriental Medical Hospital
Incheon, South Korea
NCT Number: NCT02651454
The Purpose of this trial is to investigate the efficacy and safety of Daesiho-tang and Taeeumjowi-tang on Korean obese Women with metabolic syndrome Risk factors
Looking for future studies?
Notify Me18 year–65 year
Female
Interventional
Phase 4
Incheon, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
Other names: DSHT, Elsion Granule
Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
Other names: CST
Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
Time frame: baseline, 12 weeks
Time frame: baseline, 4,8,12,16 weeks
Time frame: baseline, 4,8,12,16 weeks
Time frame: baseline, 4,8,12,16 weeks
Time frame: baseline, 4,8,12,16 weeks
Time frame: baseline, 4,8,12,16 weeks
Time frame: Screening visit, 12 weeks
Time frame: Screening visit, 12 weeks
Time frame: Screening visit, 12 weeks
Time frame: baseline, 12 weeks
Time frame: baseline, 12 weeks
Time frame: baseline, 12 weeks
Gachon University Gil Oriental Medical Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06461273
Behavior, Body Weight
Newark, New Jersey, United States
View Trial DetailsNCT06186102
Arterial Occlusive Diseases, Arteriosclerosis
Aarhus, Jutland, Denmark
View Trial DetailsNCT07204483
Behavior, Behavioral Symptoms
Naha, Okinawa, Japan
View Trial DetailsNCT06501001
Behavior, Body Weight
Toledo, Spain
View Trial Details